Survodutide
<
>
Survodutide
Survodutide

Survodutide

Survodutide B2B Inquiry Guide

  • Request current specification, packaging, and availability before ordering.
  • Share quantity, destination country, and preferred contact method for a faster quotation.
  • Ask for COA or product-related quality documents during the inquiry process.

This product page is intended for qualified business, laboratory, or research-related inquiry. Availability and permitted use depend on destination country and local regulations.

Survodutide Procurement Information

Specification Request

Confirm product name, preferred specification, quantity, and packaging requirement before quotation.

Document Support

Ask for available specification sheet, packaging details, or product-related quality documentation.

Quotation Follow-up

Use Inquiry Cart or the quote form so our team can reply with availability, lead time, and shipping communication.

Categories:

  • Description
  • Additional information

Basic Info.

Survodutide (also known as BI 456906) is a glucagon receptor/glucagon-like peptide-1 receptor (GCGR/GLP-1R) dual agonist, jointly developed by Boehringer Ingelheim and Zealand Pharma, and is intended to treat metabolic diseases such as obesity and non-alcoholic steatohepatitis.

Survodutide is a drug with an innovative mechanism of action and is expected to become a potential option for the treatment of obesity and metabolic-related diseases. Multiple clinical studies are underway to evaluate its safety and efficacy.


Request a Quote

Send your quantity, destination country, and preferred contact method. Our team will reply with availability and quotation details.

Categories

Go Back Top